만성폐쇄성폐질환(COPD) 시장 : KOL 인사이트

Explore the breakthrough potential of Dupixent for eosinophilic COPD, on the cusp of regulatory approval in the US and Europe, heralded by convincing Phase III results. Gain insights into the competitive landscape with updates on Nucala and Fasenra's clinical trials, highlighting the strategic positioning of biologics in COPD treatment. Stay informed on the latest advancements and prepare for the impact on COPD management.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (8)

ICS/LABA/LAMA triple combination therapies (10)

• Marketed therapies (10)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK), Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi), and Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate; AstraZeneca) (10)

Biological therapies (50)

• Anti-IL5 pipeline therapies (12)
  • Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (12)
• Anti-IL4/IL13 pipeline therapies (8)
  • Dupixent (dupilumab; Regeneron/Sanofi) (8)
• Anti-TSLP pipeline therapies (7)
  • Tezspire (tezepelumab; Amgen/AstraZeneca) (7)
• Anti-IL33 pipeline therapies (23)
  • Itepekimab (REGN3500/SAR440340; Regeneron/Sanofi) (9)
  • Astegolimab (RG6149; Roche) (9)
  • Tozorakimab (MEDI3506; AstraZeneca) (5)

Phosphodiesterase inhibitors (24)

• Pipeline therapies (24)
  • Ensifentrine (RPL554; Verona) (13)
  • Tanimilast (CHF 6001; Chiesi) (11)

Future treatment paradigm (11)

• Key insights summary (11)

Appendix (5)

• KOL details (5)
  • KOLs from North America (1)
  • KOLs from the EU (3)

KOL Bulletins (2)